CTMX

CytomX Therapeutics' stock has been impacted by several key events over the past six months. Positive clinical data for Varseta-M led to a stock rally, followed by a $250 million public offering of common stock. Q4 2025 earnings reported a wider-than-expected loss, but positive Varseta-M data led to a positive market reaction. Q1 2026 earnings beat forecasts, but revenue was down year-over-year. Recent terminations of programs such as CX-904 and CX-2029 have been noted as execution and scientific risks. The stock has experienced significant volatility, with a substantial increase over the past year.